Supernus Pharmaceuticals, Inc.
A maker of brain and nervous-system medicines, Supernus develops and sells branded treatments for ADHD, Parkinson's disease, epilepsy, and postpartum depression—brands like Qelbree, GOCOVRI, Trokendi XR, and ZURZUVAE. It began in 2005 as a spin-out of Shire Laboratories, founded by Jack Khattar, who then bought the very business he had led. Its name comes from Latin for "from above," a fitting label for a company born out of the lab it once ran.
Granted 38.6K · Sold 35.0K
Sold 5.4K
Granted 7.9K · Sold 18.8K
Granted 3.8K · Sold 1.6K
Granted 107.3K · Sold 107.3K
Granted 6.0K
Granted 7.5K · Sold 8.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Khattar Jack A.President, CEO, Director · 7 transactions | +1.5% | 4.40M | 38.6K | — | 35.0K |
| Hudson Frederick M.Director · 1 transaction | -8.2% | 60.4K | — | — | 5.4K |
| Gemayel GeorgesDirector · 3 transactions | -5.5% | 36.1K | 7.9K | — | 18.8K |
| Mottola FrankSVP, Chief Tech. Ops. Officer · 3 transactions | -3.4% | 18.4K | 3.8K | — | 1.6K |
| Bhatt Padmanabh P.Sr. VP of IP, CSO · 14 transactions | +2.4% | 17.5K | 107.3K | — | 107.3K |
| Dec Timothy CSenior Vice-President & CFO · 4 transactions | +58.7% | 8.1K | 6.0K | — | — |
| Horich William ToddSVP, Commercial Operations · 8 transactions | — | 4.8K | 7.5K | — | 8.9K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -176.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.